The a16z Show30 Maj 2019

a16z Podcast: The Economics of Expensive Medicines

with Andrew Lo (@AndrewWLo) and Jorge Conde (@JorgeCondeBio)

The advent of new gene and cell therapies are beginning to approach that holy grail of medicine—that of a possible cure. But they are also more expensive than any medicines ever sold before. In this episode, MIT economist Andrew Lo and a16z General Partner on the Bio Fund Jorge Conde discuss how exactly we place an economic value on a cure; the questions we still need to figure out, like who should pay for what and how; and how we need to start thinking about handling the coming influx of highly priced medicines like these into our healthcare system.

If we think about these payments as a kind of 'mortgage for a cure,' what happens when your gene therapy mortgage defaults? How would payment plans like these move between insurance plans? Lo and Conde also discuss the broader context in our healthcare system, the economics and risk of drug discovery and development overall – and finally, how our markets might just function more like biological systems than anything else.

Stay Updated:

Find a16z on YouTube: YouTube

Find a16z on X

Find a16z on LinkedIn

Listen to the a16z Show on Spotify

Listen to the a16z Show on Apple Podcasts

Follow our host: https://twitter.com/eriktorenberg

Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(1000)

The Next Frontier of AI Video Is Control

a16z General Partner Jennifer Li sits down with fal co-founder Gorkem Yurtseven and Head of Engineering Batuhan Taskaya to discuss what changes when generative video becomes fast enough to run in real...

17 Sep 39min

The AI-Native CRM

a16z’s Alex Rampell and Joe Schmidt sit down with Lightfield co-founder and CEO Keith Peiris to discuss what it takes to rethink the CRM for an AI-native world, and the unusual pivot that got him ther...

16 Sep 52min

The Age of Body Futurism | Ruby Justice Thelot

Elena Burger sits down with academic and cyber ethnographer Ruby Justice Thelot to explore the increasingly blurry line between internet culture and the real world, and how to tell the difference betw...

15 Sep 42min

Greg Brockman on Why OpenAI Says We’re Entering the AGI Era

Ben Horowitz and Erik Torenberg sit down with OpenAI co-founder and President Greg Brockman to discuss why he believes AI has entered a new phase, what OpenAI’s latest models reveal about the path to ...

14 Sep 51min

World Models, Robotics, and the Future of 3D AI

World Labs co-founder Justin Johnson joins MTS hosts Theo Jaffee and Sofia Puccini to discuss Atlas, World Labs’ latest world model, and the broader case for AI systems that understand and interact wi...

13 Sep 23min

Why Companies Are Becoming a Series of Loops | Anish Acharya on Lenny’s Podcast

a16z General Partner Anish Acharya joins Lenny Rachitsky on Lenny’s Podcast to discuss why fears of an AI-driven “permanent underclass” may be misplaced, how AI is changing the way companies operate, ...

12 Sep 1h 18min

What It Takes to Build a Startup | Andrew Chen & Matt Perault

a16z’s Matt Perault sits down with General Partner and Speedrun lead Andrew Chen on the a16z AI Policy Brief to explore what “Little Tech” actually looks like at the earliest stages, and why the reali...

11 Sep 38min

How AI Is Rewriting the Power Law of Venture Capital

a16z’s Jen Kha and David George sit down with Accolade Partners’ Aram Verdiyan to discuss how AI is changing the power law of technology investing, why the largest companies can compound advantages in...

10 Sep 49min